Understanding treatment resistance in prostate cancer @uclcancer. Tweets by Gert & team.
Joined January 2018
- Tweets 248
- Following 244
- Followers 1,232
- Likes 55
35 Photos and videos
Apr 29
Question: if an mHSPC patient has a PSA decline on primary treatment to <0.2ng/mL, does the volume of metastases at diagnosis make a difference? Answer in our latest STAMPEDE trial manuscript eur01.safelinks.protection.o…
1
3
10
508
Jan 19
How can we prevent the aggressive disease course of PTEN loss/inactive cancers? @EmilyGrist1 @ChrisSweens1 eur01.safelinks.protection.o…
1
6
13
1,818
AttardLab retweeted
Jan 16
About time! Good news for those men currently paying out of pocket for Abiraterone and great news for all men who will benefit in future. Well done @ProstateUK for your relentless campaigning to right this wrong.
Jan 16
BREAKING NEWS 📢
Abiraterone has been approved for use on the NHS for men in England with #ProstateCancer that has a high risk of spreading.
Over the next five years, this decision will save the lives of 3,000 men.
➡️ Read more: bit.ly/3NxcMYa
ALT Graphic stating: 'Abiraterone approved for more men in England', with a subtitle '3,000 lives saved in the next five years.'
1
6
26
4,243
AttardLab retweeted
23 Oct 2025
Quick overview of news in Prostate Cancer from Esmo with @Ecastromarcos @AttardLab and Axel Heidenreich
Please follow ecancer.org/en/video/12526-b…
4
7
457
AttardLab retweeted
🚨 Big News from #APCCC26 🚨
APCCC is opening a Call for Abstracts, creating new opportunities for younger investigators & the next generation of leaders in advanced prostate cancer!
Full details & submission 👉 apccc.org
📅 Key Dates:
🔹 Submission opens: 1 Sept 2025
🔹 Deadline: 14 Nov 2025, 23:59 CET
🔹 Notifications: 19 Dec 2025
✅ Complimentary registration for presenting authors. ✅ Travel grants available for LMIC investigators.
✅ Selected abstracts will be presented as posters in Lugano (30 Apr–1 May 2026).
Categories:
Advanced prostate cancer
Side effects & QoL/PROs
Global access to therapies
@Silke_Gillessen & @AOmlin
@OncoAlert 🚨
@fabioturco92
@Prof_IanD
@drjefstathiou
@Prof_Nick_James
@ChrisSweens1
@BertrandTOMBAL
@ZilliThomas
@neerajaiims
@bjartell
@PBlanchardMD
@BourlonMaite
@Albert0Briganti
@cdanicas
@Ecastromarcos
@mdesantis234
@nachoduranm
@drlouiseemmett
@stefanofanti4
@fontev1
@Nicola_Fossati
@marty_gleave
@ProfKHerrmann
@DrMHofman
@BarbaraJereczek
@ravikanesvaran
@FacsRaja
@LoebStacy
@quimmateo
@DrRanaMcKay
@amerseburger
@CaPsurvivorship
@declangmurphy
@DrPaulNguyen
@WilliamOhMD
@piet_ost
@DrSpratticus
@cnsternberg
@DrYukselUrun
@DrChoueiri
@tompowles1
@brian_rini
Ping
@nataliagandur
@bavilima
@yekeduz_emre
16
18
6,637
AttardLab retweeted
24 Oct 2025
The mHSPC space becomes more and more interesting! Come and participate in the discussions @APCCC_Lugano register via apccc.org!
Capivasertib plus abiraterone in PTEN-deficient metastatic hormone-sensitive prostate cancer: CAPItello-281 Phase III study out on Annals of Oncology
annalsofoncology.org/article…
CAPItello-281
In PTEN-deficient metastatic hormone-sensitive #ProstateCancer , adding the AKT inhibitor capivasertib to abiraterone and ADT significantly prolonged radiographic progression-free survival with manageable, expected toxicities.
Karim Fizazi
@mdesantis234
@M_SoteloLezama
@Daniel_J_George
@OncoAlert 🚨
@silkegillessen
@AOmlin
@nataliagandur
@bavilima
1
10
37
5,146
AttardLab retweeted
19 Oct 2025
@AzadOncology asking the question- do all patients need six cycles of Lu-PSMA in #PSMAaddition? Showing a nice example of complete response after two cycles on #UpFrontPSMA
13
28
1,764
AttardLab retweeted
19 Oct 2025
CAPItello-281
In de novo PTEN-deficient mHSPC (poor prognosis), capivasertib abiraterone ↑ rPFS vs pbo abiraterone (33.2 vs 25.7 mo; HR 0.81; P=0.034), OS immature. ↑ PTEN loss correlated with ↑ benefit; POTENTIAL for now
With Amplitude trial paving the way, NGS is key in mHSPC
How should we integrate this combo when triplet is already available?
@OncoAlert @myESMO #ESMO25
13 Oct 2025
#ESMO25
Ph III CAPItello 281: Capivasertib Abiraterone vs pbo Abi in PTEN-deficient de novo mHSPC
rPFS 33.2 vs 25.7 mo (HR 0.81); OS not yet mature ⚠️
A promising first in class targeted option for this poor-prognosis population
Benefit ↑ w/greater PTEN loss, emphasizing the need for biomarker based 1L treatment as seen with BRCA/HRR @OncoAlert
10
29
2,947
19 Oct 2025
Publication of CAPItello-281 Ph 3 trial in @Annals_Oncology at end of @fizazi_karim #ESMO25 👍annalsofoncology.org/article…
1
2
373
AttardLab retweeted
19 Oct 2025
Wonderful discussion by @Prof_Nick_James on EnzaRad highlighting the differences between Stampede. Lower risk group enrolled and differential effect of ARPI in higher risk group. #ESMO25 @myESMO @OncoAlert
2
12
25
1,723
19 Oct 2025
EnzaRad P3 trial confirms boundary of patient benefit sits somewhere between STAMPEDE ultra HR and NCCN HR. Working together we will use BM to define this #ESMO25
2
10
967
AttardLab retweeted
18 Oct 2025
1
2
4
515
18 Oct 2025
STAMPEDE update at #ESMO25today at noon. Landmark analysis of 7,129 pts shows PSA ≤0.2 ng/mL by 6–12 weeks strongly predicts OS in HSPC. Prognostic value modified by metastatic volume & nodal status. Abiraterone ± enzalutamide delivers deepest PSA responses & best survival.
3
6
23
1,696
AttardLab retweeted
17 Oct 2025
ALBAN #ESMO25 (atezolizumab/BCG vs BCG in MIBC) @Annals_Oncology did not ⬆️ EFS (HR0.97) unlike sasalimab & durvalumab in a similar setting. The drugs seem similar in metastatic UC so was it trial design making it different from other ICIs? EFS was defined differently.
4
27
61
6,503
13 Oct 2025
Our latest manuscript with #demichelislab - detailed analysis of ctDNA sequentially collected from metastatic prostate cancer pts receiving cabazitaxel. aacrjournals.org/clincancerr…
1
10
542
13 Oct 2025
🧪Sequential liquid biopsies reveal ctDNA features and dynamics linked to survival & resistance in advanced #ProstateCancer patients treated with cabazitaxel.
🧬 cell cycle gene amplification associates with taxane resistance
🤝Results from an international collaborative effort
226
AttardLab retweeted
9 Oct 2025
Precision medicine enters hormone sensitive prostate cancer therapeutics !
The first of many to follow
8 Oct 2025
💫🌟Niraparib Abiraterone Prednisone in HRR-deficient mCSPC.🌟💫 nature.com/articles/s41591-0… @AttardLab @neerajaiims @SandhuShahneen @EfstathiouEleni @drgotto @heatherhcheng @Dolmos77 @drenriquegrande @DRathkopf
@uclcancer @huntsmancancer @seattlecca @fredhutch @uwmedicine @PCF_Science @sloan_kettering
@OncoAlert
💥 First Phase III evidence of PARP inhibition in mCSPC!
🔹 Design: Double-blind, randomized (n=696), HRR (56% BRCA1/2)
🔹 Primary endpoint met:
• rPFS HR 0.52 (BRCA) → NE vs 26 mo
• rPFS HR 0.63 (ITT) → NE vs 29.5 mo
🔹 Time to symptomatic progression HR 0.50
🔹 OS (immature): HR 0.79, trend favoring niraparib
🔹 Toxicities: Anemia 29%, Hypertension 27%, manageable
🔹 HRR testing now essential at mCSPC diagnosis
🧠 Clinical impact:
Niraparib Abiraterone delivers significant PFS improvement in BRCA1/2 mCSPC—marking the PARPi era’s entry into hormone-sensitive disease.
@myESMO @ASCO @UroToday @NatureMedicine @Uromigos
#ProstateCancer #mCSPC #HRR #PARPi #Niraparib #PrecisionOncology #GUOnc #OncoTwitter
8
30
5,727